Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations

European Journal of Cell Biology

Volumn 96, Issue 5, 2017, Pages 476-485

  Łepek, Teresa ^a   Kwiatkowska, Anna ^b,c   Couture, Frédéric ^b,c   Ly, Kévin ^b,c   Desjardins, Roxane ^b,c   Dory, Yves ^b,d   Prahl, Adam ^a   Day, Robert ^b,c  

^a UNIVERSITY OF GDA SK   (Poland)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^d UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Cyclization; PACE4 inhibitors; Peptides stability; Proprotein convertases; Prostate cancer

Indexed keywords

3 MERCAPTOPROPIONIC ACID; 4 AMIDINOBENZYLAMIDE; AMIDE; ANTINEOPLASTIC AGENT; CARBOXYLIC ACID; FURIN; PACE4 INHIBITOR; PEPTIDES AND PROTEINS; PROTEIN INHIBITOR; PROTEIN PACE4; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PCSK6 PROTEIN, HUMAN; SERINE PROTEINASE;

ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CYCLIZATION; DRUG STABILITY; HUMAN; HUMAN CELL; IC50; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; MALE; PROSTATE TUMOR; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; ENZYME INHIBITORS; HUMANS; MALE; PROPROTEIN CONVERTASES; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES;

EID: 85018759979     PISSN: 01719335     EISSN: 16181298     Source Type: Journal    
DOI: 10.1016/j.ejcb.2017.04.001     Document Type: Article

References (50)

1. Adamska, A., Kolesinska, B., Kluczyk, A., Kaminski, Z.J., Janecka, A., Synthesis of linear and cyclic opioid-based peptide analogs containing multiple N-methylated amino acid residues. J. Pept. Sci. 21 (2015), 807–810.
2. Attard, G., Parker, C., Eeles, R.A., Schroder, F., Tomlins, S.A., Tannock, I., Drake, C.G., de Bono, J.S., Prostate cancer. Lancet 387 (2016), 70–82.
3. Bechara, C., Sagan, S., Cell-penetrating peptides: 20 years later, where do we stand?. FEBS Lett. 587 (2013), 1693–1702.
4. Becker, G.L., Lu, Y., Hardes, K., Strehlow, B., Levesque, C., Lindberg, I., Sandvig, K., Bakowsky, U., Day, R., Garten, W., Steinmetzer, T., Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J. Biol. Chem. 287 (2012), 21992–22003.
5. Brinckerhoff, L.H., Kalashnikov, V.V., Thompson, L.W., Yamshchikov, G.V., Pierce, R.A., Galavotti, H.S., Engelhard, V.H., Slingluff, C.L. Jr., Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27–35) peptide: implications for peptide vaccines. Int. J. Cancer 83 (1999), 326–334.
6. Cai, M., Hruby, V.J., Design of cyclized selective melanotropins. Biopolymers 106 (2016), 876–883.
7. Cameron, A., Appel, J., Houghten, R.A., Lindberg, I., Polyarginines are potent furin inhibitors. J. Biol. Chem. 275 (2000), 36741–36749.
8. Chan, L.Y., Craik, D.J., Daly, N.L., Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci. Rep., 6, 2016, 35347.
9. Chen, Y., Yang, C., Li, T., Zhang, M., Liu, Y., Gauthier, M.A., Zhao, Y., Wu, C., The interplay of disulfide bonds, alpha-helicity, and hydrophobic interactions leads to ultrahigh proteolytic stability of peptides. Biomacromolecules 16 (2015), 2347–2355.
10. Cheng, Y., Prusoff, W.H., Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973), 3099–3108.
11. Couture, F., D'Anjou, F., Day, R., On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. Biomol. Concepts 2 (2011), 421–438.
12. Couture, F., D'Anjou, F., Desjardins, R., Boudreau, F., Day, R., Role of proprotein convertases in prostate cancer progression. Neoplasia 14 (2012), 1032–1042.
13. Craik, D.J., Fairlie, D.P., Liras, S., Price, D., The future of peptide-based drugs. Chem. Biol. Drug Des. 81 (2013), 136–147.
14. D'Anjou, F., Routhier, S., Perreault, J.P., Latil, A., Bonnel, D., Fournier, I., Salzet, M., Day, R., Molecular validation of PACE4 as a target in prostate cancer. Transl. Oncol. 4 (2011), 157–172.
15. Dahms, S.O., Hardes, K., Becker, G.L., Steinmetzer, T., Brandstetter, H., Than, M.E., X-ray structures of human furin in complex with competitive inhibitors. ACS Chem. Biol. 9 (2014), 1113–1118.
16. Dasgupta, P., Singh, A., Mukherjee, R., N-terminal acylation of somatostatin analog with long chain fatty acids enhances its stability and anti-proliferative activity in human breast adenocarcinoma cells. Biol. Pharm. Bull. 25 (2002), 29–36.
17. Feldman, B.J., Feldman, D., The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1 (2001), 34–45.
18. Fugere, M., Day, R., Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol. Sci. 26 (2005), 294–301.
19. Gagnon, H., Beauchemin, S., Kwiatkowska, A., Couture, F., D'Anjou, F., Levesque, C., Dufour, F., Desbiens, A.R., Vaillancourt, R., Bernard, S., Desjardins, R., Malouin, F., Dory, Y.L., Day, R., Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin. J. Med. Chem. 57 (2014), 29–41.
20. Green, B.D., Mooney, M.H., Gault, V.A., Irwin, N., Bailey, C.J., Harriott, P., Greer, B., O'Harte, F.P., Flatt, P.R., N-terminal His(7)-modification of glucagon-like peptide-1(7–36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J. Endocrinol. 180 (2004), 379–388.
21. Hardes, K., Becker, G.L., Lu, Y., Dahms, S.O., Kohler, S., Beyer, W., Sandvig, K., Yamamoto, H., Lindberg, I., Walz, L., von Messling, V., Than, M.E., Garten, W., Steinmetzer, T., Novel furin inhibitors with potent anti-infectious activity. ChemMedChem 10 (2015), 1218–1231.
22. Henrich, S., Lindberg, I., Bode, W., Than, M.E., Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. J. Mol. Biol. 345 (2005), 211–227.
23. Kang, S., Zhao, Y., Hu, K., Xu, C., Wang, L., Liu, J., Yao, A., Zhang, H., Cao, F., miR-124 exhibits antiproliferative and antiaggressive effects on prostate cancer cells through PACE4 pathway. Prostate 74 (2014), 1095–1106.
24. Kerns, E.H., Di, L., Plasma stability methods. Drug-Like Properties: Concepts Structure Design and Methods, 2008, Academic Press, San Diego, 348–352 (chapter 30).
25. Khatib, A.M., Siegfried, G., Chretien, M., Metrakos, P., Seidah, N.G., Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am. J. Pathol. 160 (2002), 1921–1935.
26. Kristensen, M., Birch, D., Morck Nielsen, H., Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos. Int. J. Mol. Sci., 17, 2016.
27. Kwiatkowska, A., Couture, F., Levesque, C., Ly, K., Beauchemin, S., Desjardins, R., Neugebauer, W., Dory, Y.L., Day, R., Novel insights into structure–activity relationships of N-terminally modified PACE4 inhibitors. ChemMedChem 11 (2016), 289–301.
28. Kwiatkowska, A., Couture, F., Levesque, C., Ly, K., Desjardins, R., Beauchemin, S., Prahl, A., Lammek, B., Neugebauer, W., Dory, Y.L., Day, R., Design, synthesis, and structure–activity relationship studies of a potent PACE4 inhibitor. J. Med. Chem. 57 (2014), 98–109.
29. Lavery, H.J., Cooperberg, M.R., Clinically localized prostate cancer in 2017: a review of comparative effectiveness. Urol. Oncol., 2016.
30. Lee, S.H., Lee, S., Youn, Y.S., Na, D.H., Chae, S.Y., Byun, Y., Lee, K.C., Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug. Chem. 16 (2005), 377–382.
31. Lee, Y.H., Yun, J., Jung, J.C., Oh, S., Jung, Y.S., Anti-tumor activity of benzylideneacetophenone derivatives via proteasomal inhibition in prostate cancer cells. Pharmazie 71 (2016), 274–279.
32. Levesque, C., Couture, F., Kwiatkowska, A., Desjardins, R., Guerin, B., Neugebauer, W.A., Day, R., PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation. Oncotarget 6 (2015), 3680–3693.
33. Levesque, C., Fugere, M., Kwiatkowska, A., Couture, F., Desjardins, R., Routhier, S., Moussette, P., Prahl, A., Lammek, B., Appel, J.R., Houghten, R.A., D'Anjou, F., Dory, Y.L., Neugebauer, W., Day, R., The multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells. J. Med. Chem. 55 (2012), 10501–10511.
34. Małuch, I., Levesque, C., Kwiatkowska, A., Couture, F., Ly, K., Desjardins, R., Neugebauer, W.A., Prahl, A., Day, R., Positional scanning identifies the molecular determinants of a high affinity multi-leucine inhibitor for furin and PACE4. J. Med. Chem. 60 (2017), 2732–2744.
35. Morrison, J.F., Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 185 (1969), 269–286.
36. Nadrah, K., Dolenc, M.S., Preparation of amidines by amidoxime reduction with potassium formate. SYNLETT, 2007, 1257–1258.
37. Osapay, G., Prokai, L., Kim, H.S., Medzihradszky, K.F., Coy, D.H., Liapakis, G., Reisine, T., Melacini, G., Zhu, Q., Wang, S.H., Mattern, R.H., Goodman, M., Lanthionine-somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies. J. Med. Chem. 40 (1997), 2241–2251.
38. Qiao, L., Liang, Y., Li, N., Hu, X., Luo, D., Gu, J., Lu, Y., Zheng, Q., Endothelin-A receptor antagonists in prostate cancer treatment – a meta-analysis. Int. J. Clin. Exp. Med. 8 (2015), 3465–3473.
39. Qureshi, K., Lee, S., Lou, W., Trump, D., Gao, A., Targeting stat3 signaling in human prostate cancer cells using tyrosine kinase inhibitors. J. Clin. Oncol., 22, 2004, 3138.
40. Ritzel, U., Leonhardt, U., Ottleben, M., Ruhmann, A., Eckart, K., Spiess, J., Ramadori, G., A synthetic glucagon-like peptide-1 analog with improved plasma stability. J. Endocrinol. 159 (1998), 93–102.
41. Rubin, S., Qvit, N., Cyclic peptides for protein–protein interaction targets: applications to human disease. Crit. Rev. Eukaryot. Gene Expr. 26 (2016), 199–221.
42. Santos, G.B., Ganesan, A., Emery, F.S., Oral administration of peptide-based drugs: beyond Lipinski's rule. ChemMedChem 11 (2016), 2245–2251.
43. Seidah, N.G., Prat, A., The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11 (2012), 367–383.
44. Sewald, N., Jakubke, H.-N., Peptides: Chemistry and Biology. 2009, Wiley-VCH.
45. Spengler, J., Jimenez, J.C., Burger, K., Giralt, E., Albericio, F., Abbreviated nomenclature for cyclic and branched homo- and hetero-detic peptides. J. Pept. Res. 65 (2005), 550–555.
46. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J. Clin. 65 (2015), 87–108.
47. Tyndall, J.D., Nall, T., Fairlie, D.P., Proteases universally recognize beta strands in their active sites. Chem. Rev. 105 (2005), 973–999.
48. Wender, P.A., Mitchell, D.J., Pattabiraman, K., Pelkey, E.T., Steinman, L., Rothbard, J.B., The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 13003–13008.
49. Werle, M., Bernkop-Schnurch, A., Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30 (2006), 351–367.
50. Wu, J.N., Fish, K.M., Evans, C.P., Devere White, R.W., Dall'Era, M.A., No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 120 (2014), 818–823.